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Introduction
Lamotrigine (LTG, Lamictal) is a broad-spectrum anti-epileptic drug (AED) indicated for adjunctive therapy in children and adults with partial seizures and for generalized seizures associated with Lennox-Gastaut syndrome. More importantly, LTG is an agent frequently used in conversion to LTG monotherapy in adults with partial seizures following withdrawal from an enzyme-inducing AED. 1 The pharmacokinetic profile of LTG is complex, and selection of both dose, and rate of dose escalation and withdrawal is largely dependent upon concomitant medications interactions.
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In particular, the pharmacokinetics of LTG are substantially altered by co-medication with sodium valproate (VPA). 2, 3 VPA is a potent inhibitor of the systemic clearance of drugs that are metabolized via UDP-glucuronosyl transferse (UGT) isoenzyme system. 4,-10 The primary elimination pathway for LTG is via UGT, with UGT1A4 and UGT2B7 being chiefly involved 11 . Previous studies have clearly demonstrated the magnitude and time course of onset of this interaction. It is well established that concomitant administration of VPA can reduce LTG apparent oral clearance by about half 8 including at concentrations of VPA that are far below the proposed therapeutic range for this agent... 2 , VPA concentrations of as little as 5.6 μg/mL have been associated with 50% of maximal inhibition of LTG clearance. This interaction is not only potent but rapid as well This interaction is of particular clinical importance, in that rapidly elevated plasma concentrations of LTG that occurs with concomitant administration of VPA have been associated with an increased risk of serious dermatological reactions in both children and adults. 12 During clinical development, dosage guidelines were established for the introduction of LTG as adjunctive treatment in patients currently receiving VPA therapy. 1 Subsequently, in order to address the issue of how to manage the conversion of a patient receiving VPA monotherapy wishing to switch to LTG monotherapy, several investigators have proposed algorithms designed to optimize safety during the conversion process [13] [14] . Sale et al (2005) proposed a 4 step algorithm of weekly dose changes for both agents 13 ; the Lamictal Prescribing information was updated in 2015 to reflect this titration schedule. 1 While the algorithm was designed to allow clinicians to simultaneously switch AEDS and maintain steady lamotrigine plasma concentrations, although important critical clinically important issues were not systematically addressed. These Understanding the time course of offset or dis-inhibition will help inform the timing of LTG dose adjustments and guide clinical practice in this setting.
The objective of the current study therefore was to provide insight into the offset of this significant drug interaction to allow for further clinical guidance of LTG dosing following VPA discontinuation.
Material and Methods

Study Design
LTG pharmacokinetics were evaluated at steady-state both in the presence of and during the withdrawal of concomitant VPA. Previous data collected during a pharmacokinetic study of VPA-LTG interaction in healthy volunteers demonstrated that mean LTG elimination half-life at a VPA dose of 500 mg per day was 46.5 hours, with a range of 28 to 64 hours. 3 A co-medication period of 14 days therefore should be sufficient to achieve LTG steady-state. Similarly, an evaluation period of 14 days post-VPA discontinuation would allow for an adequate monotherapy Therefore, the low study dose of LTG was selected to allow for adequate plasma concentration modelling, while taking due precautions to ensure subject safety.
Subjects
Ten healthy adult volunteers were recruited. Inclusion criteria included age 18 to 55 years.
Exclusion criteria included tobacco use, history of hepatic or autoimmune disorders, history of hypersensitivity reactions to other medications, and current alcohol or other drug abuse. Female subjects of child-bearing potential were eligible, provided they were using adequate contraception, with the exception or oral contraceptive pills. A urine pregnancy test was administered prior to study initiation for these patients. Informed, written consent was obtained from all subjects prior to study initiation. This study was approved by the University of Wisconsin Institutional Review Board.
Study Procedures
Subjects were initiated on LTG (Lamictal) 10 mg orally every morning for 28 days and VPA (Depakote ER) 500 mg orally every morning for 14 days. Both drugs were taken simultaneously for 14 days. VPA was discontinued after the morning dose on Day 14. Morning trough (pre-dose) venous blood samples were obtained for determination of LTG and VPA concentrations on study days 14, 15, 16, 18, 20, 22, 24, 26, 28 . Samples were collected in non-heparinized tubes, allowed to clot, and the centrifuged at 2000 RPM for 10 minutes. Harvested serum was frozen at -70 o C degrees until analysis. Medication adherence was verified by interview and tablet counts.
Laboratory Analysis
Laboratory analyses were conducted at the University of Wisconsin Clinical Toxicology Lab.
Serum LTG concentrations were determined using an established gas chromatography method.
Determination of LTG serum concentrations was performed using an HPLC methodology. Briefly, LTG was measured with an optimized method using thin sorbent extraction disks and a highly selective sterically-protected bonded silica column. Serum is applied to an Empore C-8 solidphase extraction disk to isolate drug. Interferences are removed with a water wash, and the retained drug is eluted with a small volume of solvent. The eluate is directly injected onto a Zorbx Stable Bond CN column with quantification at 214 nm. The lowest limit of detection was 0.15 μg/ml and the between run precision coefficient of variation was 4.9% and serum VPA concentrations were determined using an immunoflurorometric method. Coefficient of variation for VPA at 0.7 μg/ml was 4.3%.
Statistical Analysis
Crossover study design allowed for each of the 10 subjects to serve as their own control. This sample provides sufficient power to detect a 40% difference in LTG oral clearance. Analysis of variance (ANOVA) with Scheffe post-hoc test was used to compare lamotrigine concentrations between study days. A p-value less than 0.05 was considered statistically significant. All values are displayed as mean and standard deviation (SD). For the purposes of this study, Baseline is defined as Study Day 14.
Results
A C C E P T E D
Ten subjects completed the study (7 females, 3 males). Mean subject age and weight were 29 (10) years, and 77 (22) kg, respectively. Data were analyzed for nine subjects (one subject was excluded for protocol violations). No clinically significant adverse effects were noted in any subject. LTG and VPA plasma concentrations at baseline and following VPA discontinuation are displayed in Figure 1 .
At Study day 16, two days following the final dose of VPA, plasma concentrations of were still detectable in all patients. Despite these low measured VPA concentrations, LTG concentrations were almost identical to those measured on day 14, the final day of concomitant administration.
Not until day 20, 6 days following the final dose of VPA, were LTG trough plasma concentrations significantly lower than Baseline. Between days 24-28, LTG trough plasma concentrations varied by less than 10%, and did not significantly from each other, suggesting a new steady-state had been achieved. As compared to plasma concentrations measured during concomitant administration, LTG concentrations declined by approximately 52%.
Discussion
These findings demonstrate the powerful pharmacokinetic interaction between LTG and VPA is reversible, and that de-inhibition follows a predictable time course. In patients stabilized on daily VPA plus LTG, within 3 days of discontinuing the VPA, LTG concentrations begin to decline resulting in an approximate 50% decline within 2 weeks of VPA discontinuation. This is consistent with our previous observations that at VPA trough concentrations of approximately 20 μg/ml, inhibition of LTG metabolism is near maximal, with inhibition beginning to decline at VPA concentrations below 5 μg/ml. 2 By 7-9 days following the complete disappearance of VPA from The precise mechanism underlying this important interaction is still uncertain. It has been assumed to be due to simple competitive inhibition between of UGT1A4, however, the actual mechanism is likely more complex. 5 While precise exploration of the mechanism(s) underlying this interaction is beyond the scope of this report, recent evidence supports the notion that this interaction may be due to VPA-mediated inhibition of UGT2B7 and not UGT1A4 as is commonly assumed.
LTG is primarily metabolized by glucuronyl transferases with about 90% excreted in the urine as glucuronide conjugates. 11 The major metabolite, N2-glucuronidated-LTG is inactive and is the primary metabolite found in the urine. The conversion of LTG to the N2-glucuronide conjugate is largely accomplished via UGT1A4, although UGT1A1, 1A3, 1A6, 1A7, and UGT2B7 also contribute to the formation of this metabolite to a lesser extent; enzyme kinetics of this conversion is best characterized by a mixed model including Michaelis-Mentin and Hill kinetics. 15 UGT1A4 catalyzes the N-glucuronidation of LTG at a fairly rapid rate (105 pmol/min at a supratherapeutic substrate concentration of 1500µM -plasma concentration of 381µg/mL), and appears to be responsible for the Michelis-Menten component of the total enzyme activity. The other identified enzyme, UGT2B7, appears to be responsible for the Hill kinetics with negative cooperativity, meaning that substrate binding reduces affinity for further substrate binding.
Though this enzyme has a much lower rate of conversion to the N2-glucuronidated LTG (3. 1-5.4 pmol/min at LTG concentration of 1500µM), it is responsible for 58% of the total N2-glucuronide formation activity at 25µM LTG (corresponding to theoretical plasma levels of 6.4μg/mL), and 20% of the activity at LTG concentration of 1500µM.
Although there are many common substrates acted on by the UGT family, several UGTs have certain characteristic qualities. For example, UGT1A4 acts upon tertiary amines such as LTG and somewhat upon primary amines, though it has a lower affinity for these substrates than UGT2B10. 16 UGT2B7 metabolizes a number of substrates, and is responsible for the phase II metabolism of a number of drugs and endogenous hormones. Both UGT1A4 and UGT2B7 catalyze N-glucuronidation reactions and have considerable substrate overlap.
VPA is also extensively metabolized by UGTs including UGT1A3, 1A4, 1A8, 1A9, and UGT2B7, with the majority of the glucuronide conjugates being excreted in the urine. 17 The intrinsic clearance of VPA via UGT2B7 is much higher than that of UGT1A4. VPA is generally recognized as an enzyme inhibitor, particularly of UGT. Several drugs used in epilepsy other than LTG also undergo significant glucuronidation, yet detailed interaction studies with VPA give seemingly conflicting results.
For example, ezogabine is known to undergo N-glucuronidation by UGT1A4 (as well as UGT1A1 and 1A9) [18] [19] however concurrent VPA administration shows no inhibition of ezogabine metabolism. In humans, ezogabine is primarily metabolized by UGT1A1, 1A4, and 1A9, which form the two N-glucuronidated metabolites of ezogabine; UGT2B7 does not catalyze Nglucuronidation of this drug. 18 Although UGT1A4 is a shared enzyme, concurrent incubation of While VPA is also metabolized by 1A9, again there does not appear to be a significant interaction involving these shared isoforms. 18 Another interaction worth our consideration is that between VPA and lorazepam. Lorazepam is metabolized by several UGTs -S-lorazepam appears to be primarily metabolized by UGT2B15 with lesser contributions from UGT2B4 and 2B7. 20 The other enantiomer, R-lorazepam appears to be metabolized by UGT2B4, 2B7 and 2B15, however intestinal UGTs 1A7 and 1A10 also metabolized R-lorazepam to a significant extent. Systemic clearance of lorazepam was decreased by approximately 40% in healthy volunteers receiving concomitant VPA. This change in parent drug clearance was accounted for by significantly decreased metabolic formation of lorazepamglucuronide. 21 Finally, Roland and colleagues demonstrated that in human liver microsomes expressing UGT1A4 in the presence of LTG, VPA caused negligible inhibition of UGT1A4, yet still had an effect on the production of LTG N-glucuronide. 15 Taken together, these findings while supporting that VPA is indeed an inhibitor of glucuronidation, it may not be interfering with UGT1A4. Thus, perhaps VPA should not be necessarily considered an indiscriminate inhibitor of glucuronidation. In other words, clinicians should not assume that VPA will necessarily interfere with all drugs that are metabolized via glucuronidation.
Of note, we did not screen for polymorphisms in UGT isozymes in the current study. Recent analyses have highlighted the importance of polymorphisms of UGT2B7 on the disposition of LTG 
